Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies

Moderna shares fell nearly 3% on May 12, 2026, reversing an intraday surge to $59.48, as profit-taking followed last week's rally tied to hantavirus developments, according to Perplexity Finance as of 05/13/2026. Separately, the company was ranked No. 1 on TIME's 2026 World's Most Impactful Companies list, recognizing its contributions to mRNA technology and public health, per a Fidelity news report as of 05/12/2026. This comes after Q1 earnings reported on May 1, with EPS of ($3.40), as noted by MarketBeat as of 05/13/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Moderna: core business model

Moderna develops mRNA-based medicines and vaccines, pioneering messenger RNA technology to instruct cells to produce proteins for therapeutic effects. The company, founded in 2010 and headquartered in Cambridge, Massachusetts, gained prominence with its COVID-19 vaccine, Spikevax, authorized in 2020. Its platform targets infectious diseases, oncology, rare diseases, and autoimmune disorders, with over 40 programs in development as of recent updates from its investor site.

Revenue primarily stems from product sales like Spikevax, alongside collaborations with partners such as Merck for cancer therapies. Moderna reported Q1 2026 EPS of ($3.40) for the quarter ended March 31, 2026, published May 1, 2026, per MarketBeat as of 05/01/2026. The Nasdaq-listed stock (MRNA) offers US investors exposure to biotech innovation.

Main revenue and product drivers for Moderna

Spikevax remains a key driver, though demand has normalized post-pandemic. Emerging products include mRNA-1345 for RSV, with FDA approval in 2024, and combo vaccines like mRNA-1083 for flu and COVID. Partnerships bolster the pipeline, such as with Vertex for cystic fibrosis therapies. The TIME ranking underscores Moderna's impact in accelerating vaccine development, relevant for US investors tracking biotech leaders.

Q1 results reflect R&D investments amid transitioning to commercial-stage operations. Shares traded at around $59 intraday recently before the 3% drop, per Perplexity Finance as of 05/12/2026.

Industry trends and competitive position

The mRNA sector is expanding beyond vaccines into personalized medicine and oncology, with Moderna competing against Pfizer-BioNTech, BioNTech, and CureVac. Its lipid nanoparticle delivery system provides a competitive edge. US market dominance in biotech funding supports Moderna's growth, with Nasdaq as a key listing venue for investor access.

Why Moderna matters for US investors

Listed on Nasdaq, Moderna exemplifies US biotech prowess, with significant revenue from domestic sales and government contracts. Its innovations influence healthcare costs and pandemic preparedness, directly impacting the US economy through jobs in Massachusetts and clinical trials nationwide.

Conclusion

Moderna's No. 1 TIME ranking highlights its mRNA leadership, alongside recent Q1 earnings and share price volatility. Investors monitor pipeline progress and market dynamics. The stock remains a focal point in biotech for its innovation track record.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.